Opinion on R&D in United Kingdom

Select information type

Refine your search

search
Search tips

Published within

« | 1 | 2 | 3 | 4 | 5 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

GSK: looking further ahead with Exelixis deal

GSK's partnership with genomics-based drug discovery firm Exelexis is a logical move. The pharma giant has already bolstered its weak late stage pipeline with licensing deals; Exelixis should help do the same for its early stage pipeline. GSK is successfully using its vast financial resources to compensate for the failure of its internal R&D.

Published By Datamonitor
30 Oct 2002
CommentWire
CommentWire

AstraZeneca: Exanta results biased by design

Although a new trial has found AstraZeneca's Exanta more effective than Aventis' Lovenox at cutting venous thromboembolism incidence, the trial's design does not inspire confidence in the results - or in Exanta as a VTE drug. AstraZeneca's anticoagulant has far greater potential as a replacement for warfarin for stroke prevention in atrial fibrillation patients.<BR />

Published By Datamonitor
30 Oct 2002
CommentWire
CommentWire

Liver cancer: adding radio waves may cut bleeding

Surgeons have shown a new technique to cut blood loss during removal of liver tumors. It involves delivering radio waves to the tumor site during the operation, speeding the rate at which blood clots. Since the blood loss associated with liver tumor removal currently reduces survival rates, this is positive news both for patients and the drug industry.

Published By Datamonitor
05 Nov 2002
CommentWire
CommentWire

GSK: short term bright, long term gloomy

GSK is expected to launch a number of new drugs and indications in the short to medium-term, following a series of FDA approvals. However, negative factors such as generic risk will prevent strong growth going forward. GSK needs to consider a more aggressive strategy to boost future prospects.<BR /><BR /><BR />

Published By Datamonitor
19 Dec 2002
CommentWire
CommentWire

Cancer: titanium offers hope where platinum fails

Current therapy for ovarian cancer involves chemotherapy with platinum-based agents, although over three-quarters of these tumors develop resistance to such treatment. Now, novel titanium-based anticancer compounds are in development. They demonstrate activity against tumor cells resistant to the commonly-used platinum-analogues and could usher in a new range of treatments.

Published By Datamonitor
03 Mar 2003
CommentWire
CommentWire

GSK: antidepressant leader under threat

The Chicago court ruling will see Apotex's Paxil generic impact the GSK bi-blockbuster antidepressant from 2005. Moreover, GSK's follow up antidepressant, vilazadone, appears to be struggling to proceed to market, leaving GSK with a wealth of depression expertise but a foreseeable dent in its antidepressant revenue stream.

Published By Datamonitor
07 Mar 2003
CommentWire
CommentWire

AstraZeneca: trying to differentiate Crestor

The JUPITER trial will determine whether long-term treatment with Crestor decreases the rate of major cardiovascular events in patients with average LDL cholesterol and elevated C-reactive protein levels. AstraZeneca will have to show significant advantages to effectively differentiate Crestor from other statins that are already backed by comprehensive long-term safety and efficacy data.

Published By Datamonitor
19 Mar 2003
CommentWire
CommentWire

AstraZeneca: positive follow-up data from ATAC trial

ASCO is supporting its prior recommendation for the use of AstraZeneca's Arimidex for the treatment of early stage breast cancer following a review of 47-month follow-up trial data. But Nolvadex has been the established choice for so long, it is proving difficult to get all physicians to change their prescribing habits.

Published By Datamonitor
12 May 2003
CommentWire
CommentWire

Diesel cars: sales on the up

The technological advances made in diesel engines has fuelled a steady increase in their sales across Europe. With the diesel models of some manufacturers already outselling petrol models, the only way to maintain current diesel growth rates will be if other companies commit to more specialist diesel development.<BR />

Published By Datamonitor
19 May 2003

« | 1 | 2 | 3 | 4 | 5 | » »|

No help is available.